Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Enters $25M Direct Offering Agreement

NEW YORK – OpGen announced on Tuesday that it has inked a definitive agreement with a US-based investor for a $25 million registered direct offering.

The unnamed healthcare-focused institutional investor is purchasing 2,784,184 shares of common stock and 5,549,149 prefunded warrants where each warrant is exercisable for one share of common stock, OpGen said. In a concurrent private placement, the company is issuing unregistered common share purchase warrants to purchase 4,166,666 shares of common stock.

The offering is expected to close Feb. 11 and Alliance Global Partners is acting as sole placement agent.

The share of common stock and its accompanying common warrant are being sold at a combined offering of $3.00 and the pre-funded warrant with its accompanying common warrant are being sold for $2.99, priced at-the-market under Nasdaq rules. 

The prefunded warrants are immediately exercisable at the exercise price of $.01 and can be exercised until all of the pre-funded warrants are exercised in full. Meanwhile, the common warrants will have an exercise price of $3.55 per share and will be exercisable six months after the date of issuance. The common warrants will expire five-and-a-half years from the date of issuance, OpGen said.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.